Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

PRIMARY OBJECTIVE:

I. To collect biospecimens from 1) patients who developed chemotherapy related cardiac toxicity (CRCT) and 2) patients who are at a high risk for developing CRCT.

OUTLINE: This is an observational study.

Patients undergo blood sample collection and have their medical records reviewed on study. Patients may also optionally undergo ECG on study.

Inclusion criteria

• 18 years of age or older
• Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy
• One of the following:

• Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment
• Completed chemotherapy with no cardiotoxicity at least two years post treatment
• Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity
• An understanding of the protocol and its requirements, risks, and discomforts
• The ability and willingness to sign an informed consent

Exclusion criteria

• Inability on the part of the patient to understand the informed consent or be compliant with the protocol